Modulating NO-GC Pathway in Pulmonary Arterial Hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Hypertension Research
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) pathogenesis involves altered vasoactive factors and vascular dysfunction.
• Increased oxidative stress and impaired nitric oxide (NO) signaling are key pathophysiologic features in PAH.
• NO normally inhibits vascular smooth muscle cell proliferation, preventing vessel occlusion and increased pulmonary vascular resistance.

Purpose of the Study:

• To review current information on the nitric oxide (NO) pathway in pulmonary arterial hypertension (PAH).
• To discuss the role of NO modulation in the onset and progression of PAH.
• To highlight approved NO-pathway modulating drugs for PAH treatment.

Main Methods:

• Literature review focusing on the nitric oxide pathway in PAH.
• Analysis of pathophysiologic alterations in vascular function related to PAH.
• Examination of current therapeutic strategies targeting NO modulation in PAH.

Main Results:

• NO pathway dysregulation is central to PAH pathogenesis.
• Two drug classes, phosphodiesterase-5 inhibitors (PD5i) and soluble guanylate cyclase (sGC) activators, modulate the NO pathway.
• Both drug classes demonstrate significant improvements in exercise capacity and pulmonary hemodynamics.

Conclusions:

• Targeting the NO pathway offers effective therapeutic strategies for PAH.
• PD5i are recommended for first-line PAH treatment.
• sGC activators are crucial for treating resistant or inoperable chronic thromboembolic pulmonary hypertension.